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Abstract
This review addresses relevant aspects of Chagas disease in the immunocompromised host. Chagas disease—one of the world’s most
neglected diseases—has become a global public health concern. Novel transmission modalities, such as organ transplantation, evidence of
parasite persistence in chronically infected individuals—with the potential for reactivation under immunosuppression—and the prolonged
survival of immunosuppressed patients call for an appraisal of the disease in this particular setting. The management and outcome of solid
organ transplantation in the infected recipient with special focus on heart transplantation is addressed. The guidelines for management and
the outcome of the recipients of organs from infected donors are discussed, and comments on haematopoietic stem cell transplantation are
included. Finally, Chagas disease in other situations of impairment of the immune system, such as HIV/AIDS and autoimmune diseases, are
considered. Immunosuppression has become an increasingly frequent condition that might modify the natural history of Trypanosoma cruzi
infection. A number of strategies are available for Chagas disease management in the immunosuppressed patient. First, according to recent
recommendations from the health authorities in Argentina, most infected patients would beneﬁt from being treated at diagnosis. This has
not been validated for patients with different immunosuppressive disorders. A different strategy would involve treating only patients with
documented reactivation (either parasitaemia or clinical manifestations). These different approaches are discussed. To reach a diagnosis of
parasitaemia, monitoring is essential, either with conventional methods or with molecular techniques that are not yet available in all centres.
Collaborative studies are needed to improve the level of evidence, which will allow for better guidelines.
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Introduction and general considerations
Chagas disease is endemic in 21 Latin American countries,
where 8–10 million people are infected [1]. Because of
recent human migration patterns, the disease is becoming a
serious global public health concern in non-endemic areas,
with a signiﬁcant number of infected individuals residing
there [2,3]. The infection is produced by the protozoan
parasite Trypanosoma cruzi, and is transmitted either by
vectors, by unscreened blood transfusion, or vertically from
an infected mother to the fetus and orally. Newer
transmission modalities include organ transplantation [4].
Human disease has two distinct phases: acute infection and
chronic infection. In adults, the acute infection seems to
resolve spontaneously even if untreated; but, without speciﬁc
treatment, the infection continues and leads to chronic
infection or disease. Chronic T. cruzi infection can be
asymptomatic for life or, in c. 30% of patients, may evolve
into irreversible disease of the heart (27%), the oesophagus,
the colon (6%), and/or the peripheral nervous system (3%)
[5]. Also, chronic infection may have spontaneous reactiva-
tions with intermittent parasitaemia with low counts of
circulating parasites that remain undetectable with conven-
tional diagnostic tools [5], such as the Strout test. Specu-
lation on the clinical signiﬁcance of this transient parasitaemia
is beyond the scope of this review.
In the acute phase of infection, diagnosis is achieved with
direct parasitological tests, including the examination of whole
blood preparations and a concentration method (the Strout
test) [6], and also with serological tests [7]. In the chronic
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stage, diagnosis is performed with serological tests. The most
commonly used are: the enzyme immunoassay, the indirect
haemagglutination assay, and the indirect immunoﬂuorescence
assay. All have good sensitivity but less than optimal speciﬁcity,
and show considerable variation in the reproducibility and
reliability of results [8]. A new ELISA Test System (Ortho-Clin-
ical Diagnostic) is available for blood screening purposes [9].
The indirect immunoﬂuorescence assay and radioimmunopre-
cipitation assay are used mainly as ‘conﬁrmatory’ tests [9].
Improved PCR-based assays, which are available in some areas
[10], have been used in clinical research, and seem to
constitute a useful tool for diagnosis [10]. New quantiﬁcation
techniques have been developed [11], and might result in
beneﬁts for clinical management. However, at present, the
WHO still recommends that at least two different serological
methods of testing be used for T. cruzi infection diagnosis [12]
(Table 1).
During the 1960s and 1970s, two drugs were introduced for
treatment: nifurtimox (8–10 mg/kg daily) and benznidazole
(5–8 mg/kg daily). When benznidazole is administered for
30–60 days, parasitic cure is achieved in 60–100% of acute
cases. Nifurtimox is considered to be a second-line treatment
drug, with more toxic effects and needing a longer treatment
duration. Recent evidence supports the idea that trypanocidal
treatment might modify the outcome of long-term chronic
infections, and might achieve a 20–60% cure rate for infections
acquired up to 10 years previously [13,14]. Comparisons of
the two drugs are described in Table 2 (www.HIV-druginter
actions.org (last accessed 8 January 2014); www.cdc.gov/
parasites/chagas/health_professionals/tx.html (last accessed 8
January 2014)) [15,16].
In the 1980s and early 1990s, it was shown that infected
individuals with serious impairment of the immune system,
such as transplant recipients and those living with human
immunodeﬁciency virus (HIV) infection, were at risk of severe
forms of reactivation [4]. Almost at the same time, transmis-
sion of infection from infected organ donors to na€ıve
recipients was described [17].
Some aspects of Chagas disease management in immuno-
suppressed patients are proposed and summarized in non-val-
idated tables and algorithms.
Chagas Disease and Transplantation
Different clinical scenarios can be found in the context of solid
organ transplantation and Chagas disease. Pre-transplant
evaluation of donors and recipients with serotesting is routine
in most endemic areas. This evaluation is also being performed
or at least considered in non-endemic areas that have a
signiﬁcant number of migrants from Latin America [17,18].
The Infected Recipient
Many would suggest treating infected asymptomatic recipients.
However, there is no documented evidence that pre-trans-
plant treatment leads to better results, and the adverse side
effects of trypanocidal drugs in patients with terminal organ
failure makes their use almost impossible [19]. A strict
protocol of sequential monitoring—to search for parasitaemia
and other evidence of reactivation—after transplantation is
crucial, and is possibly the best approach [20]. A proposed
algorithm for follow-up is shown in Fig. 1.
The presence of circulating parasites in the blood is
considered to indicate reactivation if identiﬁed with direct
TABLE 1. Diagnostic tools in Trypanosoma cruzi chronic infection and in reactivation with immunosuppression
Tools Blood Body ﬂuids Tissue specimens Comments
Serology Yes NA NA IHA–EIA–IFA
No diagnostic value for reactivation
Optical microscopy Yes (trypomastigotes)
No stains
Yes (trypomastigotes)
No stains
Stains: haematoxylin
and Eosin, Giemsa
(amastigote nests)
High parasitic burden for blood and body ﬂuids
Strout test (concentration test) Yes (trypomastigotes) Yes (trypomastigotes) NA High parasite burden
kDNA PCR (no quantiﬁcation) Yes Yes Yes Positive with low parasite burden
qPCR (quantiﬁcation of DNA in
peripheral blood)
Yes NA NA Positive with low parasite burden
Cut-off for clinical use to be determined
PCR identiﬁcation
of DTUs (I–VI)
Yes Yes Yes Positive with low parasite burden
Identiﬁcation of different DTUs
Culture Yes Yes Yes Cumbersome procedure
Xenodiagnoses Yes – – Cumbersome procedure
No clinical application at present
DTU, discrete typing unit; EIA, enzyme immunoassay; IFA, indirect immunoﬂuorescence assay; IHA, indirect haemagglutination assay; kDNA, kinetoplasmid DNA; NA, not
applicable; qPCR, quantitative PCR.
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methods of detection that detect a large number of
circulating parasites (Strout test) in the previously infected
individual. Molecular methods are more sensitive, but the
positive results should be interpreted with caution in the
infected transplant recipient. Ideally, either the tests should
be repeatedly positive, or the parasitic load should be
quantiﬁed, and cut-off levels would have to be deﬁned to
trigger therapeutic actions.
TABLE 2. Comparison of trypanocidal drugs used for Chagas disease treatment
Benznidazole Nifurtimox Comments
Total daily dose (mg/kg) 5–8 8–10 –
Times per day Twice Three times –
Administration Oral Oral –
Treatment duration (days) 60 60–120 –
Metabolism Hepatic Hepatic—NADPH P450 reductase –
Mechanism of action Inhibition of protein and RNA synthesis
in Trypanosoma cruzi
Free oxygen radical formation –
Metabolic pathway Renal excretion 60–70% Renal excretion of metabolites –
Anorexia, weight loss ++ +++ –
Nausea, vomiting ++ ++ Early in the course of
treatment for beznidazole
No need to discontinue
Fatigue, headache,
insomnia, vertigo, seizures
++ +++ Sometimes need to discontinue
(nifurtimox more severe)
Peripheral neuropathy,
polyneuropathy
+++ (late in the
course of treatment)
+++ (early in the
course of treatment)
Discontinuation
Dermatitis, rash ++ ++ Not necessary to stop treatment
unless there is a purpuric rash
Bone marrow suppression +++ +++ Leukopenia, thrombocytopenia
Discontinuation
Interactions with
immunosuppressive drugs
Possible with drugs that
interact with cytochrome P450
Not known Close monitoring of adverse events
Interactions with antiretrovirals Possible with drugs that
interact with cytochrome P450
Not known Close monitoring of adverse events
Warnings Alcohol, aspirin, anticoagulants
Mutagenicity in experimental animals
Alcohol, aspirin –
Contraindications Pregnancy, severe kidney
and liver insufﬁciency
Pregnancy, severe kidney
and liver insufﬁciency
–
Donor
Serotesting
IHA-EIA-IFA
Some may use RIPA*
Living
Negative Positive
Parasitemia
Positive
Treatment
Negative
Treatment
optional
Deceased
NegativePositive
Organ donation 
except heart
Recipient
Serotesting
IHA-EIA-IFA
Some may use RIPA*
Negative Positive
< 50 years > 50 years
Treatment for 60 days 
with trypanocidal drugs 
if not contraindicated. 
Caveat: treatment side 
effects could be more 
severe in patients with 
terminal organ failure
Study parasitemia  with 
higly sensitive methods 
(PCR - qPCR)** 
Positive 
parasitemia
Negative
parasitemia
No treatmentTRANSPLANTATION
Positive donor or positive recipient:
Sequential monitoring for early parasitemia detection          
- Months 0–2
- Months 3–4
- Monthly for 2 years
- Weekly for 2 months after increase in 
immunosuppression (i.e.: rejection treatment)  
Positive donor and negative recipient:
Transmission may occur Positive recipient:
Reactivation may occur
FIG. 1. Proposed algorithm for Chagas disease management in patients with solid organ transplantation: authors’ recommended management. EIA,
enzyme immunoassay; IFA, indirect immunoﬂuorescence assay; IHA, indirect haemagglutination assay; qPCR, quantitative PCR; RIPA,
radioimmunoprecipitation assay;.
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In recent years, transplantation has become available in
Chagas-endemic areas. As a result, organ transplantation in
T. cruzi-infected individuals has become more common, with a
steadily growing number of infected individuals on the waiting
list [20].
Most of the experience in chronically infected individuals is
related to kidney transplant [20,21] or heart transplant [22,23]
recipients, with only a very few cases in liver transplant
recipients.
In kidney recipients, reactivation has been shown to occur
mainly within the ﬁrst post-transplant year or after a signiﬁcant
increase in immunosuppression. The incidence of reactivation
varies greatly among transplant centres [20], and has been
documented as being 8.3–17%. The relationship with induction
or rejection treatments and with maintenance immunosup-
pression protocols has not been thoroughly studied, and no
signiﬁcant data are available. It is likely that an increased risk of
reactivation is to be expected during intensiﬁcation of
immunosuppression. Hence, special care should be taken after
the treatment of a rejection episode, and monitoring should be
intensiﬁed for a period of time [20].
Reactivation can be completely asymptomatic, and only
parasitaemia will show the recurrence of the infection. When
clinical manifestations appear, signs of subcutaneous involve-
ment—reminiscent of erythema nodosum—and panniculitis
are present, with tenderness and characteristic limb involve-
ment (Table 3) [24–26]. If diagnosis and, consequently, treat-
ment are delayed, lesions can evolve into painful ulcers.
Myocarditis and encephalitis have also been described, but are
unusual. A good response to 30–60 days of treatment, with
adequate graft and patient survival after long-term follow-up
has been reported. Chronic stigmata of Chagas disease such as
cardiomyopathy, although not thoroughly studied, have not
been reported.
For liver transplantation, the experience is still scant, but
more programmes are including infected patients in the waiting
list. Preliminary clinical observations show that the incidence
of reactivation varies among centres [20], but does not seem
to differ greatly from what has been described for the kidney
[20].
Heart Transplantation
Individuals with T. cruzi infection may develop severe heart
disease, as the myocardium and the heart conduction system
are the main targets of chronic parasitic infection. Heart
transplantation is now accepted as the treatment of choice for
chronic chagasic cardiomyopathy, in spite of the risk of
infection reactivation [22,27]. This condition has become, over
time, the second to third leading cause of heart transplantation
in Brazil [23,28]. Reactivation has been reported to occur in
26.5% [29] to 42.9% [22] of patients. Reactivation ranges from
asymptomatic parasitaemia to fever, subcutaneous involve-
ment, and myocarditis, and is more frequent in but not limited
to the ﬁrst post-transplant year [23]. This condition has to be
differentiated from rejection, especially if amastigote nests are
not found in the endomyocardial biopsies. On a preliminary
observation of endomyocardial biopsy specimens, this may
prove to be a difﬁcult challenge [30].
The endomyocardial biopsy specimens show lymphocytic
inﬁltrates with oedema and areas of necrosis [31] in both
situations. The identiﬁcation of the agent with standard
histological staining techniques provides the diagnosis and
shows the amastigote nests. Polyclonal antibodies against
T. cruzi or its antigens and tissue-based PCRs have been used
for diagnostic purposes, thus allowing earlier and more
accurate diagnosis of the disease [32]. In general, reactivation
occurs early after transplantation, and relapses after comple-
tion of treatment may be as frequent as one to eight episodes
per patient [33]. Systematic and sequential monitoring, which
allows for early diagnosis and a good response to treatment,
TABLE 3. Chagas disease reactiva-
tion patterns in patients with solid
organ transplants (SOTs) and
human immunodeﬁciency virus
(HIV) infection
SOT HIV Comments
Relationship with ‘net state
of immunosuppression’
MMF, > 2 g daily <200 CD4+ cells/lL Described by some but not all
Asymptomatic/parasitaemia Yes Yes Signiﬁcance of positive parasitaemia
deserves further research
Panniculitis/erythema
nodosum-like
+++ + Pathogenesis of clinical differences
deserves further research
Encephalitis + +++ Pathogenesis of clinical differences
deserves further research
CNS mass + +++ Pathogenesis of clinical differences
deserves further research
Myocarditis +++ ++ Predominant in heart recipients
Mortality + +++ Predominant in heart recipients
Dependent on AIDS
progression and reactivation site
CNS, central nervous system; MMF, mycophenolate mofetil.
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has been shown to result in an expected survival [22,23].
Prospective monitoring of blood specimens from all infected
recipients is used to identify the circulating parasite. Direct
parasitological tests such as the Strout method will give
positive results only if a large number of parasites are present.
PCR-based tests have been beneﬁcial, as they have allowed
earlier identiﬁcation of parasitaemia [22]. Also, all available
tissue specimens, including protocol endomyocardial biopsy
specimens, should be evaluated for the presence of amastigote
nests [20]. Serology has no utility in the diagnosis of
reactivation. It has been suggested to try to keep immuno-
suppression as low as possible and reach the difﬁcult
equilibrium required to avoid not only rejection but also
reactivation. For this purpose, some authors suggest avoiding
induction therapy with antilymphocytic drugs and refraining
from using micofenolic acid for maintenance immunosuppres-
sion [23]. However, not all authors have had the same
experience [17]. Prophylactic treatment early after transplan-
tation was of no beneﬁt in a small cohort of patients, and did
not prevent reactivation [27,29].
Mortality related to Chagas disease reactivation has been
reported to be 0.3%, and the survival rates are no different
from those of other heart transplant recipients [27].
The Infected Donor
In the early 1990s, transmission of T. cruzi from known
infected donors to negative recipients was reported for kidney
transplant recipients [34,35]. Some years later, it was shown
that transmission was not always the rule, and that it could be
detected quite early by a systematic search for parasitaemia.
These data provided the basis for the sequential monitoring of
infection transmission [21]. Approximately 10 years later, the
ﬁrst cases of accidental transmission from unscreened donors
were reported in the USA [36,37].
Transmission has been documented to occur in 18% of
recipients of kidney transplants from infected donors, with
only one having clinical disease [21], and in 22% of liver
transplant recipients [38], with transmission being identiﬁed
through parasitaemia monitoring, and with no clinical mani-
festations of disease. Nonetheless, not all transplant teams—
even in highly endemic areas—accept organs from infected
donors, or only do so if no better donor is available in a
reasonable time-span. Sequential monitoring tools should be
available for post-transplant follow-up, and a high level of
suspicion, in addition to appropriate diagnostic methods,
should be used if such a patient presents with clinical
manifestations of disease transmission. The usefulness of
monitoring has recently been highlighted by Cura et al. [39],
who showed that not all uninfected recipients of organs from
the same donor become infected, and that, when infection
occurs, different typing units (DTUs) or different lineages are
involved in the process. It seems, however, that different
lineages might have special tissue tropism, even if more than
one DTU is found within circulating parasites. Which potential
donors should be screened in non-endemic areas and which
are the best testing methods [18] and monitoring guidelines
[20] have been debated extensively, and there is recent
publication concerning these issues [40].
The use of prophylactic benznidazol remains controversial
[9,18,19]. Some advocate its use, but randomized evidence is
lacking. Others, owing to the potential toxicity of trypanocidal
drugs, to the low reactivation and transmission incidence, and
to the good outcome achieved with treatment, would rather
monitor for active infection and treat accordingly [18–20]. We
favour the approach of sequential and timed monitoring, and
treat according to evidence of either reactivation or trans-
mission of infection [20] (Fig. 1).
Haematopoietic Stem Cell Transplantation
(HSCT)
In the last 20 years, it has been shown that HSCT is feasible in
patients with chronic asymptomatic T. cruzi infection. The risk
of reactivation varies from 17% to 40% for autologous or
allogeneic HSCT [41]. It has also been suggested that patients
from endemic areas or born to mothers from such areas be
serotested before the use of chemotherapy or conditioning
regimens [42]. Monitoring for reactivation and early treatment
have been shown to reduce the number of cases of serious and
potentially fatal disease [43]. An additional concern in this
particular setting is the safety of the blood used for whole
blood or blood product transfusions. In endemic areas, blood
banks do screen for T. cruzi infection, but this practice is not
universal in non-endemic countries [44]. In all, there are
surprisingly few reports on reactivation after HSCT.
Chagas Disease and HIV Infection
When the AIDS epidemic reached Latin American countries,
where Chagas disease is endemic, it was not long before these
two conditions were recognized as co-infecting the same
patient. The ﬁrst reports of T. cruzi infection or Chagas disease
in patients living with HIV were published in the 1989–1992,
and came essentially from Brazil, Argentina, and the USA [45–
48]. In Argentina and Brazil, this association made it necessary
to include Chagas disease as an AIDS-deﬁning illness.
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In a systematic review recently published of the last
20 years of the AIDS epidemic in association with Chagas,
Almeida et al. [26] were able to estimate that c. 22 000
patients were co-infected, but this low number of co-infections
probably depended on under-reporting and misdiagnosis. Also,
most cases had chronic T. cruzi infection and were young men,
in accordance with the demographics of the AIDS epidemic.
Interestingly, serodiagnosis was negative in 5.4% of cases,
whereas xenodiagnosis was positive in 93% and haemoculture
in 79% [26], probably reﬂecting the severe impairment of the
immune system that made serology become negative in spite
of actual chronic infection, and also the different diagnostic
modalities at the various centres. In a different study,
co-infection was diagnosed in 1.3% of HIV patients, and
reactivation of Chagas was more frequent in older women
[49]. Others have found a prevalence of co-infection of 5%,
with a remarkably high incidence in intravenous drug users
[50]. These sparse data on co-infection prevalence emphasize
the need for accurate identiﬁcation of T. cruzi infection in
individuals living with HIV especially if they are natives of or
residing in highly endemic areas. This knowledge would serve
the purpose of enabling targeted diagnostic procedures and
timely therapeutic intervention.
Reactivations of T. cruzi infection are dependent on the
severity of the immune defect; they have been described more
often with a CD4+ T-cell count of <200/mm3, and are associated
with a high level of parasitaemia. The presence of co-infection
with a lowCD4+ count and a high level of parasitaemia would be
a predictor of Chagas disease progression with organ involve-
ment [25, 51–53]. However, a higher CD4+ T-cell count does
not rule out the clinical reactivation diagnosis, and isolated
detection of circulating parasites does not conﬁrm it. Therefore,
quantiﬁcation of parasitic load with molecular strategies and
cut-off points—yet to be determined—would help to charac-
terize the reactivation and would allow for early treatment. The
beneﬁt of this attractive strategy has yet to be proven in
collaborative multicentre clinical trials [25,31,51] (Fig. 2). De
Freitas et al. found that ‘the quantiﬁcation of T. cruzi load by
qRT-PCR showed signiﬁcant differences between groups; the
highest parasitemia was observed in patients infected with HIV/
T. cruzi with Chagas disease reactivation (median 1428.90
T. cruzi/mL), followed by patients with HIV/T. cruzi infection
without reactivation (median 1.57 T. cruzi/mL) and patients with
Chagas disease without HIV (median 0.00 T. cruzi/mL)’ [25]. The
diagnosis of parasitaemia may be elusive if only a small number of
parasites are circulating, or delayed [52] if conventional
methods are used. Diagnosis could be improved with molecular
diagnostic tools (PCR of kinetoplasmid DNA and sDNA
sequences, competitive PCR, and real-time quantitative PCR),
but these have yet to be tested in large clinical trials in the setting
of this co-infection [25,31,51].
Also, it should be noted that a rise in HIV viral load has been
described during reactivation of T. cruzi infection [53], and that
the parasite count can be quite high in cases of reactivation
[26]. Reactivation could be limited to parasitaemia, and a mix
of lineages and typing units are found circulating in peripheral
*Parasitemia: Idencaon of parasites in blood; qPCR: signicant values yet to be
determined
HIV +
Chagas disease serology
Negative Positive
Parasitemia once, post -treatment
Annually thereafter
Treatment according to guidelinesCD4+  200 cel/L
Parasitemia*
CD4+  200 cel/L
Parasitemia post treatment
Monthly until CD4+  200 cell/L
Annually thereafter
Treatment and follow up
According to guidelines
Secondary prophylactic
treatment until CD4+  200
cel/L, during 3–6 months.
(See text for details)
Without Clinical
Reactivation
With Clinical
Reactivation and 
disease control
Positive
Parasitemia
Negative
Parasitemia
Evaluate re-treatment
FIG. 2. Human immunodeﬁciency virus (HIV)/AIDS: proposed strategies in Chagas disease-endemic areas or in patients with risk of co-infection.
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blood samples from immunocompromised individuals [54,55].
It is possible that HIV infection could have an impact on the
genetic diversity of T. cruzi at the time of reactivation.
However, no differences from HIV-negative patients have
been found, and no association between reactivation and
genotyping was found in some studies [54,55].
Neurological and myocardial involvement is to be expected
as the most frequent organ lesion in reactivated Chagas
disease. Involvement of other organs has been described, but is
quite unusual [56] (Table 3).
Neurological manifestations of Chagas reactivation may
present with encephalitis or with a pseudotumoral mass
producing focal symptoms. These need to be differentiated
from other diseases involving the central nervous system
(CNS) in HIV/AIDS patients, especially toxoplasmosis
[24,47,57–60]. Differential diagnosis of a neurological disease
in a patient with HIV and T. cruzi infection requires imaging and
laboratory tests on the cerebrospinal ﬂuid and eventually on
the brain tissue biopsy specimen. Trypomastigotes detected by
direct examination have been found in 78% of cerebrospinal
ﬂuid samples, and diagnosis was achieved with the ﬁnding of
amastigote nests, stained with haematoxylin and eosin and
Giemsa, in the brain biopsy specimen in c. 15% of cases [26].
When molecular tools for parasite identiﬁcation in neurolog-
ical specimens were used, a prevalence of certain lineages was
found that could suggest a special neurotropism within the
different DTUs [61,62], contradicting previous observations. A
complete description of the diagnostic algorithm for neuro-
logical disease in the context of HIV and T. cruzi co-infection
exceeds the purpose of this review, but sufﬁce it to say that
aetiological diagnosis can be difﬁcult and that more than one
pathogen may be involved. Thus, some have proposed that the
therapeutic management of CNS involvement in HIV patients
either co-infected with T. cruzi or with risk factors for this
parasitic infection should include trypanocidal drugs with
antitoxoplasma treatment until the diagnostic algorithm is
completed and a ﬁnal diagnosis is achieved [63,64]. Manifes-
tations of heart disease are mostly those of heart insufﬁciency
and of arrhythmias [65]. Endomyocardial biopsy will show a
prevalence of inﬂammation, with lymphocytic and macrophage
inﬁltrates; ﬁbrosis and amastygote nests are also frequently
found [26,66–69]. Ideally, the differential diagnosis should
determine what symptoms can be attributed to HIV/AIDS and
its treatment, to Chagas progression itself, or to actual
reactivation resulting from immunosuppression.
Treatment adjustments for each scenario might then be
needed. If parasitic loads are high, they might be predictive of
organ involvement, and patients could beneﬁt if treated
pre-emptively, especially those with low CD4+ cell counts
or with increases in HIV viral load [25,53]. However, this
strategy has not been evaluated in detail with appropriately
powered studies. Reactivation should be treated with trypan-
ocidal drugs (Table 2). The use of allopurinol for treatment
remains controversial, with only a small number of published
reports. However, it has been used under some circum-
stances, alone or in combination with benznidazole, and
especially in patients with severe cardiac insufﬁciency and
during pregnancy [30,70–72].
The conventional treatment duration is 60 days. However,
in patients with CNS involvement, there is no clinical evidence
to recommend a deﬁnitive treatment duration. It should be
adapted to each individual in a single-patient decision-making
process. Experimental treatment protocols with posaconazole
and with ravuconazol are being investigated, but preliminary
results have not yet been released. Some case reports can be
found in the literature [73,74].
Prophylaxis before reactivation with trypanocidal drugs has
not been recommended for the T. cruzi-infected patient living
with HIV. However, updated guidelines from the Ministry of
Health [75], based on recent pathogenic ﬁndings, state the need
to treat all T. cruzi-infected individuals irrespective of co-infec-
tions. All individuals younger than 19 years, irrespective of
Chagas disease status, and patients from 19 to 50 years of age,
if asymptomatic or with initial symptoms of heart disease,
should receive one of the conventional trypanocidal drugs for
60 days. This recommendation is irrespective of immune
status, and is becoming the standard of care in Argentina.
Secondary prophylaxis is recommended with benznidazol 2.5–
5 mg/kg three times weekly after treatment of reactivation and
if the CD4+ count remains below 200/mm3 [75].
The rate of mortality resulting from co-infection is high. It
varies from 55% to 79%, and depends on the characteristics of
the infection and the organs involved. A timely diagnosis and
early initiation of therapy—trypanocidal and antiretroviral—
considerably improve the outcome [76,77]. The rate of
mortality resulting from this co-infection is dependent on
HIV/AIDS progression, on the timing of Chagas reactivation
diagnosis and treatment, and on organ involvement. Timing
varies from 1 day to 5 years after the diagnosis of Chagas
reactivation [26]. The mortality rate in patients with CNS
disease is higher than in those with other organ manifestations
of Chagas disease (Table 3).
Chagas Disease and other Immune
Disorders
International experience with Chagas disease in other immu-
nocompromised patients is scarce [78], and comprises mostly
case reports. Most are related to systemic lupus erythemat-
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osus (SLE) [73,79,80], and only one has described the
association of Chagas reactivation with rheumatoid arthritis,
in a patient who presented with chagasic polymyositis [81].
In 1980, one study described the treatment of Chagas
disease in ten patients with SLE and in six with neoplasms. All
of the patients, except four with neoplastic diseases, received
prophylactic treatment with nifurtimox 8 mg/kg daily, for
60 days. No evidence of reactivated Chagas disease was found
in either group: with and without previous immunosuppressive
treatment (three SLE and two cancer patients), and with and
without nifurtimox (four cancer patients) [79]. Another six
cases have been described in the literature (four SLE and two
rheumatoid arthritis) [78,80,81], and were treated with
benznidazol. Four of these cases were published by Pinazo
et al. [78]. Diagnosis of reactivation was based on a positive
PCR result, and all patients were treated: Two patients
responded to treatment; in one patient, follow-up with PCR
could not be performed, and in the last case posaconazole was
added to the treatment and a negative PCR result was ﬁnally
achieved. The small amount of experience prevents the
formulation of useful guidelines in this setting, with the possible
exception of having Chagas disease reactivation in mind.
Finally, when high doses of corticosteroids are used to
obtain an immunosuppressive effect, there is no evidence to
support the pre-emptive use of trypanocidal drugs [82]. During
the period of corticosteroid use, monitoring of reactivation
could be the best approach. The same could be said for other
immune treatments where evidence for more speciﬁc guide-
lines is lacking.
Conclusions
A century after its discovery, much has been accomplished in
our knowledge and understanding of Chagas disease. The
disease is spreading fast, and it can now be found far from the
classic endemic areas. Immunosuppressed individuals can be or
become infected with this parasite, and may have unusual
clinical manifestations. Comprehensive follow-up guidelines,
the availability of molecular diagnostic methodologies and new
treatment options will allow for a better understanding of the
real burden and outcomes of this infection in the setting of
immunosuppressive states.
However, much more needs to be achieved. The greatest
challenges remain the development of new and accessible
treatment options with fewer adverse effects, and the design
and execution of multicentre studies to validate the diagnostic
and therapeutic strategies in all of the different immunosup-
pressive scenarios.
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